Compare · DXCM vs PSTV
DXCM vs PSTV
Side-by-side comparison of DexCom Inc. (DXCM) and PLUS THERAPEUTICS Inc. (PSTV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and PSTV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 1148.9x PSTV ($25.7M).
- PSTV has been more active in the news (12 items in the past 4 weeks vs 6 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 3 for PSTV).
- Company
- DexCom Inc.
- PLUS THERAPEUTICS Inc.
- Price
- -
- -
- Market cap
- $29.58B
- $25.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 6
- 12
- Recent ratings
- 25
- 3
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
PLUS THERAPEUTICS Inc.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium NanoLiposomes, a patented radiotherapy for patients with recurrent glioblastoma, which is in the Phase 1 dose-finding clinical trial. The company is also developing DocePLUS, a patented chemotherapy for patients with solid tumors that is in Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy for patients with ovarian cancer. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
Latest PSTV
- Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
- Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
- Director Andrews Ronald Asbury converted options into 922 shares (SEC Form 4)
- Chief Financial Officer Sims Andrew John Hugh Macintyre converted options into 2,985 shares, increasing direct ownership by 43% to 9,941 units (SEC Form 4)
- Director Hawkins Richard J converted options into 922 shares, increasing direct ownership by 152% to 1,529 units (SEC Form 4)
- Director Van Es-Johansson An converted options into 922 shares (SEC Form 4)
- Director Clowes Howard converted options into 922 shares, increasing direct ownership by 87% to 1,981 units (SEC Form 4)
- Chief Executive Officer Hedrick Marc H converted options into 16,439 shares, increasing direct ownership by 59% to 44,483 units (SEC Form 4)
- Director Guse Kyle converted options into 922 shares (SEC Form 4)
- Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding